Cambridge, United States
Kytopen is a pioneering biotechnology startup with a primary focus on expediting the discovery, development, and manufacture of gene-modified cell therapies. The company's flagship product, Flowfect®, integrates microfluidics and automation to transform the delivery of genome engineering materials to cells. This innovative approach offers significant advantages in terms of speed, scalability, and cost-effectiveness compared to existing alternatives. In May 2023, Kytopen unveiled Flowfect Discover™, an automated high-throughput genome engineering platform, and announced strategic partnerships with leading Contract Development and Manufacturing Organizations (CDMOs) and translational academic medical centers. These developments position Kytopen to address manufacturing challenges during the discovery stage, fostering faster and more cost-effective innovation.
Founded in 2017 and headquartered in the United States, Kytopen secured a noteworthy $30.00M Series A investment on 28th September 2021, attracting support from a diverse group of investors including MassVentures, The Engine, Horizon Ventures, TBD Angels, Alexandria Venture Investments, Northpond Ventures, Selvedge Venture, John Ballantyne, and Michael Chambers.
The company's commitment to advancing cell therapy processes positions Kytopen as a promising player in the burgeoning biotechnology and healthcare industries.
